A division of
For 27 years Encap has led the way in providing solutions for oral drug delivery.
Encap was established in Livingston, Scotland in 1989 to exploit an emerging new oral drug delivery technology. The core business technology is in the liquid filling of two-piece hard capsules and the company has grown organically and steadily over the years and has made significant investments in people, equipment, resources and moved to a new facility in 2005.
The company has remained as a specialist company focused on its core liquid and semi-solid fill technology . Encap works with companies in the pharmaceutical and nutraceutical industries to help develop and manufacture their products.
Liquid-fill based formulation is one of the fastest growing sectors of the drug delivery market, increasing at a rate of 30% per annum. This is due to the number of highly potent chemical and biological-based drugs moving through development pipelines today particularly for cancer treatments. To meet this growing demand, Encap has recently expanded the size of its facilities by nearly 50% to provide clients with high containment manufacturing capabilities.
Encap has also been a pioneer in the development of encapsulation technology to produce oral Vancomycin. Vancomycin capsules release antibiotic directly into the gastro-intestinal tract and have become the first line treatment for life threatening diseases associated with the hospital superbug C. Difficile, which is becoming an increasing problem in Europe. Encap is the exclusive manufacturing facility for various marketing authorizations throughout Europe and as a result, Encap supplies 90% of the European market with this product.
Copyright © Encap